Mass-Spectrometry-Based Method To Quantify in Parallel Tau and Amyloid β 1-42 in CSF for the Diagnosis of Alzheimer's Disease

被引:27
|
作者
Pottiez, Gwenael [1 ]
Yang, Li [1 ]
Stewart, Tessandra [1 ]
Song, Ning [1 ]
Aro, Patrick [1 ]
Galasko, Douglas R. [2 ]
Quinn, Joseph F. [3 ,4 ]
Peskind, Elaine R. [5 ,6 ]
Shi, Min [1 ]
Zhang, Jing [1 ,7 ,8 ]
机构
[1] Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98104 USA
[2] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92093 USA
[3] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA
[4] Portland VA Med Ctr, Portland, OR 97239 USA
[5] VA Puget Sound Hlth Care Syst, Northwest Network VISN 20, Mental Illness Res Educ & Clin Ctr, Seattle, WA 98108 USA
[6] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA
[7] Peking Univ, Hlth Sci Ctr, Dept Pathol, Beijing 100083, Peoples R China
[8] Third Hosp, Beijing 100083, Peoples R China
基金
美国国家卫生研究院;
关键词
Alzheimer's disease; mass spectrometry; SRM; diagnosis; biomarker; cerebrospinal fluid; tau; amyloid beta; A beta(42); HUMAN CEREBROSPINAL-FLUID; ANTIBODY-FREE; QUANTIFICATION; BIOMARKERS; PROTEIN; ASSOCIATION; BETA-AMYLOID((1-42)); REPRODUCIBILITY; PEPTIDES; ASSAYS;
D O I
10.1021/acs.jproteome.6b00829
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Alzheimer's disease (AD), the most common form of dementia, afflicts about 50 million people worldwide. Currently, AD diagnosis is primarily based on psychological evaluation and can only be confirmed post-mortem. Reliable and objective biomarkers for prognosis and diagnosis have been sought for years. Together, tau and amyloid beta 1-42 (A beta(42)) in cerebrospinal fluid (CSF) have been shown to provide good diagnostic sensitivity and specificity. Additionally, phosphorylated forms of tau, such as tau pS181, have also shown promising results. However, the measurement of such markers currently relies on antibody-based immunoassays that have shown variability, leading to discrepant results across laboratories. To date, mass spectrometry methods developed to evaluate CSF tau and A,1342 are not compatible. We present in this article the development of a mass-spectrometry-based method of quantification for CSF tau and A beta(42) in parallel. The absolute concentrations of tau and A beta(42) we measured are on average 50 ng/mL (7-130 ng/mL) and 7.1 ng/mL (3-13 ng/mL), respectively. Analyses of CSF tau and A beta(42), in a cohort of patients with AD, mild cognitive impairment, and healthy controls (30 subjects), provide significant group differences evaluated with ROC curves (AUC(control-AD) and AUC((control-MCI)) = 1, AUC((MCI-AD))) = 0.76), with at least equivalent diagnostic utility to immunoassay measurements in the same sample set. Finally, a significant and negative correlation was found between the tau and A beta peptides ratio and the disease severity.
引用
收藏
页码:1228 / 1238
页数:11
相关论文
共 50 条
  • [1] CSF tau and amyloid β1-42 (Aβ42) as possible biomarkers of Alzheimer disease
    Ravid, R
    Kamphorst, W
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2005, 238 : S298 - S298
  • [2] Total-tau, Aβ1-42 and Ubiquitin in CSF in the diagnosis of Alzheimer disease
    Iqbal, K
    [J]. EUROPEAN PSYCHIATRY, 2002, 17 : 76S - 76S
  • [3] CSFβ-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease:: The effect of APOE ε4 allele
    Smach, Mohamed Ali
    Charfeddine, Bassem
    Lammouchi, Turkia
    Harrabi, Imed
    Ben Othman, Leila
    Dridi, Hedi
    Bennamou, Soufien
    Limem, Khalifa
    [J]. NEUROSCIENCE LETTERS, 2008, 440 (02) : 145 - 149
  • [4] Amyloid β(1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease
    Schoonenboom, NSM
    Pijnenburg, YAL
    Mulder, C
    Rosso, SM
    Van Elk, EJ
    Van Kamp, GJ
    Van Swieten, JC
    Scheltens, P
    [J]. NEUROLOGY, 2004, 62 (09) : 1580 - 1584
  • [5] CSF tau protein and β-amyloid (1-42) in Alzheimer's disease diagnosis:: discrimination from normal ageing and other dementias in the Greek population
    Kapaki, E
    Paraskevas, GP
    Zalonis, I
    Zournas, C
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2003, 10 (02) : 119 - 128
  • [6] Amyloid beta 1-42 and tau in the cerebrospinal fluid of renal failure patients for the diagnosis of Alzheimer's disease
    Shea, Yat Fung
    Chu, Leung-wing
    Mok, Ming-yee Maggie
    Lam, Man-Fai
    [J]. JOURNAL OF NEPHROLOGY, 2014, 27 (02) : 217 - 220
  • [7] Amyloid-β(1-42), Total Tau, and Phosphorylated Tau as Cerebrospinal Fluid Biomarkers for the Diagnosis of Alzheimer Disease
    Mulder, Cees
    Verwey, Nicolaas A.
    van der Flier, Wiesje M.
    Bouwman, Femke H.
    Kok, Astrid
    van Elk, Evert J.
    Scheltens, Philip
    Blankenstein, Marinus A.
    [J]. CLINICAL CHEMISTRY, 2010, 56 (02) : 248 - 253
  • [8] Advances in the development of biomarkers for Alzheimer's disease -: From CSF total tau and amyloid-(β1-42) proteins to phosphorylated tau and amyloid-β-antibodies
    Hampel, H
    Teipel, S
    Faltraco, F
    Brettschneider, S
    Goernitz, A
    Buerger, K
    Moeller, HJ
    [J]. MOLECULAR NEUROBIOLOGY OF ALZHEIMER DISEASE AND RELATED DISORDERS, 2004, : 134 - 156
  • [9] Highly increased CSF tau protein and decreased β-amyloid (1-42) in sporadic CJD:: a discrimination from Alzheimer's disease?
    Kapaki, E
    Kilidireas, K
    Paraskevas, GP
    Michalopoulou, M
    Patsouris, E
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2001, 71 (03): : 401 - 403
  • [10] Interrelations between CSF Soluble AβPPβ, Amyloid-β 1-42, SORL1, and Tau Levels in Alzheimer's Disease
    Alexopoulos, Panagiotis
    Guo, Liang-Hao
    Tsolakidou, Amalia
    Kratzer, Martina
    Grimmer, Timo
    Westerteicher, Christine
    Jiang, Meizi
    Bujo, Hideaki
    Diehl-Schmid, Janine
    Kurz, Alexander
    Perneczky, Robert
    [J]. JOURNAL OF ALZHEIMERS DISEASE, 2012, 28 (03) : 543 - 552